YM BioSciences Enrolls First Patients in Colorectal Cancer Trial
Posted on: Wednesday, 1 August 2007, 09:06 CDT
YM BioSciences has enrolled the first five patients within the 50-patient initial cohort of its Phase II trial with nimotuzumab in combination with irinotecan for colorectal cancer patients who have previously failed irinotecan-containing regimens.
Recruitment of the first cohort is expected to be completed within approximately eight months, following which data on the primary endpoints, response rate and safety, will be reported.
The single-arm trial will enroll approximately 100 patients in Canada. The trial will enroll two 50-patient cohorts consecutively, with the first cohort receiving irinotecan on one of the conventional dosing schedules with weekly dosing of nimotuzumab and the second cohort receiving irinotecan on one of the conventional dosing schedules with nimotuzumab every two weeks.
David Allan, chairman and CEO of YM BioSciences, said: "Results from this trial could further continue to confirm the unique safety profile of our EGFR-targeting antibody while establishing its efficacy, and expanding the prospective market for nimotuzumab into one of the largest cancer patient populations."
Nimotuzumab is a humanized monoclonal antibody that targets the epidermal growth factor receptor. YM BioSciences has also received clearance from Health Canada for a trial with nimotuzumab in pediatric glioma, while recruitment in a Phase I trial in patients with non-small-cell lung cancer is nearing completion in Canada and continues in the arm of the trial being conducted in Korea.
Source: Datamonitor
Related Articles
- Hollis-Eden Pharmaceuticals Commences Phase I/II Clinical Trial With APOPTONE(TM) (HE3235) in Late-Stage Prostate Cancer Patients
- Ym Biosciences Announces Nimotuzumab Colorectal Cancer Trial First Cohort is Closed to Accrual
- Bionovo Enrolls First Patient on Phase 1/2 Clinical Trial of BZL101 for the Treatment of Advanced Breast Cancer
- Ambit Biosciences Begins Dosing in Leukemia Trial
- Ambit Biosciences Begins Dosing Patients in Phase I Clinical Trial of Lead Kinase Inhibitor AC220
- CVBT Announces It Will Begin U.S. FDA-Authorized Clinical Trials in Diabetic Patients With Open Wounds
- Predix Pharmaceuticals Announces Initiation of Phase Ib Clinical Trial in Alzheimer's Patients; Provides Initial Dose Study Update
- Pro-Pharmaceuticals Announces Dosing of Cancer Patient With DAVANAT/5-FU in a Phase II Clinical Trial at Medical Oncology & Hematology, P.C.
- Human Genome Sciences Completes Patient Enrollment in a Phase 2 Clinical Trial of HGS-ETR1 for the Treatment of Colorectal Cancer
- CTI to Report Results From STELLAR 3 Pivotal Trial of XYOTAX(TM) in Non-Small Cell Lung Cancer Ahead of Previous Guidance
 |
 |
User Comments (0)
RSS Feeds